Vigil Neuroscience(VIGL) - 2024 Q1 - Quarterly Results

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update – Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 7, 2024 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microgli ...